Bluebird bio — Q2 2023 Earnings Presentation
16 slides from Bluebird bio's earnings presentation, Aug 8, 2023
Slide 1: Q2 Earnings Call & Commercial Launch Update
Q2 Earnings Call & Commercial Launch Update August 8, 2023 NASDAQ: BLUE Exhibit 99.1
Slide 2: Forward-looking statements
CONFIDENTIAL This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations
Slide 3: Outlook and Q2 2023 key business updates
CONFIDENTIAL 3 Outlook and Q2 2023 key business updates Andrew Obenshain, chief executive officer Commercial launch progress Tom Klima, chief commercial and operating officer Upcoming milestones Andrew Obenshain, chief executive officer Q&A – joined by Chris Krawtschuk, chief financial officer Rich
Slide 4: To give patients and their families more bluebird days
CONFIDENTIAL 4 TO GIVE PATIENTS AND THEIR FAMILIES MORE BLUEBIRD DAYS
Slide 5: bluebird occupies a unique strategic position as a standalone gene therapy company
CONFIDENTIAL bluebird occupies a unique strategic position as a standalone gene therapy company 5 • 10+ years of gene therapy research • 180+ patients treated • 8 clinical trials • Established track record for LVV platform • 2 FDA approvals • 3rd BLA under priority review • 2 ongoing US launches • T
Slide 6: bluebird's five-year vision
CONFIDENTIAL bluebird’s five-year vision Multi billion-dollar opportunity with TDT and SCD in the US Competitive marginFocused, synergistic commercial footprint Wholly- owned global rights 6
Slide 7: Second Quarter 2023 Key Business Highlights
CONFIDENTIAL Second Quarter 2023 Key Business Highlights 71. Cash balance contains $45m in restricted cash.; 2. Without the release of our restricted cash, we estimate our cash, cash equivalents and marketable securities as of June 30, 2023 will be sufficient to fund our operations into the second q
Slide 8: Launch momentum building as on-boarded QTCs gain experience and accelerate patient enrollment
CONFIDENTIAL Launch momentum building as on-boarded QTCs gain experience and accelerate patient enrollment 2022 1H 2023 2023 2H 2023 WAVE 1 First 5 QTCs Activated 100% have started a patient 60% have started multiple patients August – Sept 2022 WAVE 2 6-10 QTCs Activated 40% have started a patient P
Slide 9: Delivering a consistent manufacturing process is essential for patients, families and providers
CONFIDENTIAL Delivering a consistent manufacturing process is essential for patients, families and providers 9 Apheresis and Cell Collection Drug Product Manufacturing and Testing Drug Product Ready to Ship Infusion and Recovery 70-90 Days Occurs at QTC Occurs at CMO Bulk of time spent on release te
Slide 10: lovo-cel potential approval based on robust and longest follow-up of any SCD gene therapy
CONFIDENTIAL lovo-cel potential approval is based on the most robust and longest follow-up of any gene therapy program for SCD Data as of Aug 11, 2022 10*50 patients treated includes patients from HGB-205, HGB-206 Group A, Group B and Group C and HGB-210 BLA under priority review for the treatment f
Slide 11: Durability and long-term follow-up drive gene therapy decisions
CONFIDENTIAL Durability and long-term follow-up are the most important factors driving gene therapy decisions and key differentiators for lovo-cel 11 …of patients would consider gene therapy if recommended by their doctor … of physicians are driven by efficacy and long-term follow-up, and not modali
Slide 12: SKYSONA for cerebral adrenoleukodystrophy
CONFIDENTIALAugust 8, 2023 SKYSONA® for cerebral adrenoleukodystrophy Commercial • 40 potentially eligible patients; anticipate 5–10 patient starts in 2023 • 5 patient starts since launch; 4 QTCs activated; zero ultimate denials across government and commercial payers Clinical • 67 patients treated
Slide 13: Upcoming milestones
CONFIDENTIAL First to market gene therapy for inherited hemoglobin disorders in the U.S. Proving our commercial model Significant value driver o PDUFA date Dec. 20, 2023 o Commercial launch expected early 2024, if approved o Continued launch expansion through 2023 o 40-50 QTCs by end of 2023 o Antic
Slide 14: Potential for significant value creation in the near-term
CONFIDENTIAL 14 Potential for significant value creation in the near-term Unique strategic position Strong competitive advantage Focus on profitability
Slide 15: CONFIDENTIAL 15
CONFIDENTIAL 15
Slide 16: Thank you